Drugs / [18F]DPA-714
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02405403 | Mar 2015 → Sep 2016 | amyotrophic lateral sclerosis | University Hospital, Tours | Withdrawn | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT05238961 | Apr 2028 | carotid artery disorder | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| Phase 1 | NCT03968445 | Oct 2019 → Oct 2028 expected | myocardial infarction | University of Alabama at Birmingham | Active not recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07583147 | Jun 2026 → Sep 2029 expected | intracerebral hemorrhage | University Hospital, Toulouse | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05128903 | Jul 2022 → Oct 2035 expected | medulloblastoma | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04320030 | Jun 2020 → Jul 2021 | triple-negative breast carcinoma | Institut Cancerologie de l'Ouest | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05672082 | Oct 2023 → Mar 2025 | glioma | Center Eugene Marquis | Withdrawn | No outcome recorded |
| — | NCT02305264 | Mar 2012 → Sep 2018 | primary progressive multiple sclerosis, relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]DPA-714 | “There is a great need for a non-invasive methodology enabling the quantification of translocator protein overexpression in PET clinical imaging. [18F]DPA-714 has emerged as a...” PMID 28178885 ↗ Feb 20179“The purpose of the study is to see if positron emission tomography and magnetic resonance imaging (PET/MRI) with an investigational drug called \[18F\]DPA-714 will show...” NCT03968445 ↗ “QARIN 1 is a study of \[18F\]DPA-714 Translocation Protein (TSPO) Positron Emission Tomography (PET) for longitudinal, quantitative assessment of brain neuroinflammation...” NCT05128903 ↗ |
| Known as | Fludeoxyglucose(18F)-labeled DPA-714 | “This clinical imaging substudy will use the small molecule translocator protein (TSPO) ligand, Fludeoxyglucose(18F)-labeled DPA-714, to compare neuroinflammation in individuals...” NCT05238961 ↗ |
| Modality | Diagnostic / imaging agent | “using the PET ligand \[18F\]DPA-714” NCT03968445 ↗ |
| Route | Intravenous | “are injected intravenously” NCT04320030 ↗ |